

ARTICLE OPEN



The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK

Rupert R. A. Bourne^{1,2}, Malik Moledina³, Augusto Azuara-Blanco⁴, George M. Saleh⁵, James E. Self⁶, Sobha Sivaprasad⁷, Srilakshmi M. Sharma⁸, Andrew Ross^{2,9}, Rose M. Gilbert¹⁰, Maram E. A. Abdalla Elsayed⁸, Won Young Moon⁸, Manjo Doug¹, Pádraig J. Mulholland^{10,11}, Alexander C. Day¹⁰, Vito Romano¹², Geraldine V. Hoad¹³, Madina Kara¹⁴, Ailish Murray¹⁵, Louise Gow¹⁶, Faruque Ghanchi¹⁷, Praveen J. Patel¹⁰, Richard P. Gale¹⁸, Christiana Dinah^{19,20}, Keith Valentine¹⁴, Cathy Yelf¹³, Vanessa Poustie²¹, NIHR Ophthalmology Specialty Group* and Executive Group of UK Clinical Eye Research Strategy*

© The Author(s) 2024

OBJECTIVES: To validate and update the 2013 James Lind Alliance (JLA) Sight Loss and Vision Priority Setting Partnership (PSP)'s research priorities for Ophthalmology, as part of the UK Clinical Eye Research Strategy.

METHODS: Twelve ophthalmology research themes were identified from the JLA report. They were allocated to five Clinical Study Groups of diverse stakeholders who reviewed the top 10 research priorities for each theme. Using an online survey (April 2021–February 2023), respondents were invited to complete one or more of nine subspecialty surveys. Respondents indicated which of the research questions they considered important and subsequently ranked them.

RESULTS: In total, 2240 people responded to the survey (mean age, 59.3 years), from across the UK. 68.1% were female. 68.2% were patients, 22.3% healthcare professionals or vision researchers, 7.1% carers, and 2.1% were charity support workers. Highest ranked questions by subspecialty: Cataract (prevention), Cornea (improving microbial keratitis treatment), Optometric (impact of integration of ophthalmic primary and secondary care via community optometric care pathways), Refractive (factors influencing development and/or progression of refractive error), Childhood onset (improving early detection of visual disorders), Glaucoma (effective and improved treatments), Neuro-ophthalmology (improvements in prevention, diagnosis and treatment of neurodegeneration affecting vision), Retina (improving prevention, diagnosis and treatment of dry age-related macular degeneration), Uveitis (effective treatments for ocular and orbital inflammatory diseases).

CONCLUSIONS: A decade after the initial PSP, the results refocus the most important research questions for each subspecialty, and prime targeted research proposals within Ophthalmology, a chronically underfunded specialty given the substantial burden of disability caused by eye disease.

Eye (2024) 38:1947–1957; <https://doi.org/10.1038/s41433-024-03049-6>

INTRODUCTION

Ophthalmology is a rapidly growing research area in the UK recruiting on average more than 15,000 patients into clinical research trials annually with most National Health Service (NHS) trusts participating in eye research [1]. Ophthalmology is one of the leading areas of novel treatments [1] and in the past few decades we have seen the introduction of novel diagnostic and treatment modalities that have markedly improved outcomes in people with

eye diseases. Despite active research within ophthalmology, there are still unanswered questions about prevention, diagnosis, and treatment of eye conditions and sight loss, half of which is presumed avoidable (although the UK lacks nationally-representative population-based prevalence data) [2]. Funding for eye research is limited [3], so it is important to identify the unanswered questions of highest clinical importance so that research targeting greatest needs can be well invested for the benefits of patients and public in the future [4].

¹Vision and Eye Research Institute, School of Medicine, Anglia Ruskin University, Cambridge, UK. ²Department of Ophthalmology, Cambridge University Hospitals, Cambridge, UK. ³Imperial College NHS Foundation Trust, London, UK. ⁴Centre for Public Health, Queen's University Belfast, Belfast, UK. ⁵Research, Cataract and Adnexal Dept, Moorfields Eye Hospital, London, UK. ⁶University of Southampton, Southampton, UK. ⁷NIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK. ⁸Dept of Ophthalmology, Oxford Eye Hospital, Oxford University Hospitals NHS Trust, Oxford, UK. ⁹Aswan University Hospital, Aswan, Egypt. ¹⁰NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. ¹¹Centre for Optometry & Vision Sciences, School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, UK. ¹²Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. ¹³Macular Society, Andover, UK. ¹⁴Fight for Sight, London, UK. ¹⁵Moorfields Eye Charity, Moorfields Eye Hospital, London, UK. ¹⁶Eye care and living well services, Royal National Institute of Blind people, London, UK. ¹⁷Bradford Teaching Hospitals, Royal Infirmary, Bradford, West Yorkshire, UK. ¹⁸York Hospital, University of York, York, UK. ¹⁹Department of Ophthalmology, London North West University Healthcare NHS Trust, London, UK. ²⁰Brain Sciences, Imperial College London, London, UK. ²¹NIHR Clinical Research Network, University of Liverpool, Liverpool, UK. *Lists of authors and their affiliations appear at the end of the paper. Group Information: A list of the members of the NIHR CRN Ophthalmology Specialty Group can be found by accessing this link: <https://www.nihr.ac.uk/explore-nihr/specialties/ophthalmology.htm>. Group Information: A list of the members of the Executive Group of the UK Clinical Eye Research Strategy can be found by accessing this webpage: <https://ukeyeresearchstrategy.ac.uk>. ✉email: rb@rupertbourne.co.uk

Received: 20 January 2024 Revised: 20 March 2024 Accepted: 22 March 2024
Published online: 29 May 2024

The UK Vision Strategy was developed in 2008 to set the framework to address the issues on visual impairment in society and research was identified as one of the important strategies [4]. The Vision 2020 UK Eye Research Group was formed subsequently as part of the Vision 2020 initiative to minimise avoidable visual impairment as well as to reduce the impact of unavoidable sight loss [5]. It aimed to set priorities for the research agendas using well-constructed methods by collaboration with the James Lind Alliance (JLA) [4]. JLA is a non-profit organisation that has been working in partnership with stakeholders including patients, their representatives, and clinicians to set research priorities in a wide range of conditions since 2004. The JLA Priority Setting Partnerships (PSPs) reflect the views of current NHS service users and clinicians to prioritise funding for research that is of high clinical relevance.

The Sight Loss and Vision PSP was formed in 2012 to launch a project for eye research priority setting in collaboration with the JLA [4]. This was overseen by a steering committee made up of diverse backgrounds of patients, clinicians, and the representatives from sight loss organisations and the project was funded by the College of Optometrists, Fight for Sight, National Institute for Health and Care Research (NIHR) Moorfields Biomedical Research Centre, Royal National Institute of Blind People, Royal College of Ophthalmologists, and UK Vision Strategy. In 2013, their Sight Loss and Vision Loss Report published top 10 lists of research priorities across 12 ophthalmology subspecialties following surveys and consultations with more than 2000 ophthalmology stakeholders, supported by the JLA [4]. This was the first time in the world that research priorities were set in ophthalmology based on the systematic approach of reaching consensus from service users and providers [5].

However, there is still room for more patient-centred research, especially in those subspecialties that carry high clinical burden in the NHS [1]. There is also a growing role of commercial studies in the UK which may affect the paradigm of future eye research in the UK [1]. In addition, there have been emerging new eye treatments available in the NHS over the last decades and new models of care designed to make the services more efficient. The Covid-19 pandemic has further introduced some changes to our clinical practice and treatment goals. As such, it is time to revisit the original research priorities to ensure they still reflect current health needs.

The NIHR Clinical Research Network (CRN; which will become the NIHR Research Delivery Network in late 2024) has supported a transformation in the strength of England's research delivery system, promoted the successful delivery of studies and underpinned the dramatic expansion of health research participation. The CRN's Ophthalmology Specialty Group represents Ophthalmology within this network and oversees clinical research into medical and surgical treatments of eye diseases, optometry, visual rehabilitation and other key areas within the broader discipline of vision sciences [6]. The CRN's Ophthalmology Specialty Group initiated a UK Clinical Eye Research Strategy in 2020 [7]. This strategy started with a major initiative to update the previous James Lind Alliance (JLA) Sight and Vision Loss Priority Setting Partnership (PSP) [4]. The results are the subject of this report.

METHODS

In January 2021, a meeting was convened with the original JLA facilitator involved in 2013 to look at exploring a suitable methodology to validate and update the research priorities already identified from this report. We sought a pragmatic and novel approach as an updated PSP methodology did not exist at that time. A two-phase process was agreed.

Phase 1: Twelve ophthalmology research themes/sub-specialties identified from the 2013 Sight and Vision Loss JLA report [4] were allocated to five Clinical Study Groups (CSGs), which cover 9 different

subspecialties. The formation of CSGs is an initial output of the UK Clinical Eye Research Strategy, and each is chaired by an ophthalmologist with a strong clinical research record (GS, AAB, JS, SS, SS). Each Chair was tasked with convening a committee of diverse stakeholders to collectively review the top 10 research priorities of each of these themes. The consensus from the five CSG areas was that the majority of JLA research priority questions remained valid as they were generally very broad in scope. When considered appropriate, CSG committees refined some original questions and added others.

Phase 2: An online survey was designed using SurveyMonkey software (SurveyMonkey Inc., San Mateo, California, USA; the online survey's landing page is shown in Appendix 1). The survey went live on 19 April 2021 and closed in February 2023. A formal communication and dissemination strategy (Appendix 2) was agreed with the NIHR which included distribution of the survey link to a wide range of organisations across the UK including the Ophthalmology Specialty Group leads for each region of England and devolved nations. A direct contact person for each organization was established (usually the communications lead) to promote and disseminate the survey. In advance of this, the NIHR worked with the project team to produce a press release with a direct link to the survey. An NIHR press release had a Quick Response (QR) code added as another method to direct respondents to the online survey. Each organization sent the survey to all of its members as well as adding the links on to e-newsletters, direct emails to their members with the survey links above and promoting via their own organization websites and via Twitter (a social media website, now known as X).

National and local charities and professional organisations were involved in its dissemination strategy which aimed to maximise diversity, for example among minority ethnic groups and across all four devolved nations.

Respondents were able to enter anonymized data, in response to questions regarding demographics of the respondents, which included questions regarding age, sex, ethnicity, nation within the UK, and whether respondents were health care professionals, vision researchers, charity support workers or patients and carers. One or more of the nine surveys could be selected for completion by respondents from the following subspecialties: cataract, cornea, childhood-onset disorders, glaucoma, neuro-ophthalmology, optometry, refractive disorders, retinal disease, and uveitis.

Within each of these subspecialties, there were two tasks. The first task presented at least 10 research questions and requested the respondent to indicate which they felt was important. Each research question was also accompanied by a lay explanation. The second task listed only the research questions which the respondent had indicated were important and requested the respondent to rank these questions in a scale 1–10. A freetext option was optional for respondents to add comments. Descriptive statistics were used for the analysis involving frequency distribution, central tendency, and variability of the data set.

RESULTS

A total of 2240 people responded to the survey, with an average age of 59.3 years; 87.9% were from England, 5.5% from Scotland, 4.4% from Wales, and 2.2% from Northern Ireland. Of those respondents who gave their sex, 704 (31.9%) were male and 1501 (68.1%) female. 1527 (68.2%) respondents were patients, 158 (7.1%) carers, 499 (22.3%) healthcare professionals or vision researchers, and 48 (2.1%) charity support workers. In terms of ethnicity, 1959 (87.5%) respondents identified as white, 139 (6.2%) as Asian/ Asian British, 36 (1.6%) as Mixed/Multiple ethnic groups, and 31 (1.4%) as Black/African/Caribbean/Black British. Demographics of healthcare practitioners and non-healthcare practitioners are given in Fig. 1.

The research question most commonly ranked as of highest priority is given in Fig. 2 for each of the nine subspecialties. These and all top 10 research priorities for each of the 9 subspecialty surveys are presented in Tables 1–3.

Highest ranked questions by subspecialty can be summarized as follows: cataract (prevention), cornea (improving microbial keratitis treatment), optometric (impact of integration of ophthalmic primary and secondary care via community




Fig. 1 Proportion of healthcare practitioners (black bars) and non-healthcare practitioner respondents (grey bars) by gender, age and ethnicity.




Fig. 2 Most popular high priority question selected by respondents in each survey.

optometric care pathways), refractive (factors influencing development and/or progression of refractive error), childhood onset (improving early detection of visual disorders), glaucoma (effective and improved treatments), neuro-ophthalmology (improvements in prevention, diagnosis and treatment of neurodegeneration affecting vision), retina (improving prevention, diagnosis and treatment of dry age-related macular degeneration), uveitis (effective treatments for ocular and orbital inflammatory diseases). Understanding the cause and most effective medical management for thyroid eye disease was also highlighted as an important research priority.

DISCUSSION

Priority Setting Partnerships enable clinicians, patients and carers to work together to identify and prioritise evidence-based uncertainties in particular areas of health and care that could be answered by research. This informs researchers and research funders about priorities so that they can tailor their research making it as meaningful as possible and targeted to those people who most need it while making a wider impact. We have described an iterative process that first established wide stakeholder engagement within each of the subspecialties of Ophthalmology, then reviewed and refined the original 2013 JLA outputs of the PSP [4], and finally disseminated these research

questions to a large group of 2240 respondents. The results provide a 'refresh' of the most important research questions for each of these subspecialties of Ophthalmology a decade after the initial PSP.

Comparing this latest work with that of the original PSP, the residence of respondents was very similar, differing by less than 1 percentage point for each of the nations (original PSP respondents: England 89%, Scotland 6%, Wales 4%, Northern Ireland 1%). Average age of the original PSP was 65.7 years which was slightly higher than the average age of 59.3 years in this recent survey. The sex of respondents was relatively similar to the original PSP (males 38%, females 62%) and the proportion of healthcare professional respondents (16% in the original PSP). The total number of respondents was also similar (2220 participated in the original PSP). Ethnicity of respondents was not reported in the original PSP.

Within the refractive error, cataract and glaucoma subspecialties, the top priority research question remained the same in both the original PSP and this recent survey, yet there was variance among other subspecialties in terms of highest ranked questions. The design of the original PSP and this most recent survey is of course different involving different respondents, and the purpose of the recent survey was not to repeat the original PSP but rather to provide an up-to-date perspective on what a wide group of stakeholders judge as most important.

Table 1. Top 10 research priorities for cataract, cornea, optometric, refractive topics.

CATARACT 283 respondents	% of those responding to this survey who judged this research question to be important	Average ranking of this research question by respondents On a scale of 1–10 (1 most important, 10 least)
Q1 How can cataracts be prevented from developing?	66.43% (188 respondents)	2.97
Q2 What is the cause of cataract? How do cataracts form?	45.23% (128 respondents)	3.14
Q3 How can cataract surgery outcomes be improved?	53.71% (152 respondents)	3.38
Q4 How can cataract progression be slowed down?	51.24% (145 respondents)	3.74
Q5 What alternatives to treat cataracts other than cataract surgery are being developed?	49.12% (139 respondents)	3.87
Q6 What is the best measure of visual disability due to cataract?	37.46% (106 respondents)	3.89
Q7 How safe is bilateral simultaneous surgery?	23.32% (66 respondents)	4.03
Q8 Can the return of cloudy or blurred vision after cataract surgery known as posterior capsule opacity (PCO) or secondary cataract be prevented?	60.78% (172 respondents)	4.09
Q9 Can retinal detachment be prevented after cataract surgery?	47.35% (134 respondents)	4.12
Q10 Should we be looking at developing or using certain emerging or existing technologies in cataract care?	32.51% (92 respondents)	4.40
Q 11 Should accommodative lenses be developed for cataract surgery?	44.17% (125 respondents)	4.45
Q12 What are the roles of telemedicine/remote medicine, AI, electronic patient records, smart theatres, OCT, biometry and other technologies in the future of cataract care?	24.03% (68 respondents)	4.84
Q13 What are the outcomes for cataract surgery among people with different levels of cognitive impairment (whatever the cause but including dementia, stroke, neurological conditions, head injuries)?	22.61% (64 respondents)	5.05
CORNEA 140 Respondents		
Q1 How can microbial keratitis treatment be improved?	23.57% (33 respondents)	3.00
Q2 What is the cause of Keratoconus and can it be prevented?	46.43% (65 respondents)	3.11
Q3 How can we prevent Keratoconus progression?	40.71% (57 respondents)	3.26
Q4 How can dry eye treatment be improved?	46.43% (65 respondents)	3.53
Q5 How can quality of life of contact lenses wearer for Keratoconus disease be improved?	29.29% (41 respondents)	3.59
Q6 How can the rejection of corneal transplants be prevented?	43.57% (61 respondents)	3.80
Q7 How can diagnosis of corneal infections be improved and how can corneal infection be prevented in high-risk individuals?	28.57% (40 respondents)	3.81
Q8 How can detection of progression in Keratoconus patients be improved ?	35.00% (49 respondents)	3.86
Q9 How to standardize the diagnosis and monitoring of dry eye?	35.71% (50 respondents)	3.89
Q10 How can ocular surface disease in children, such as blepharokeratoconjunctivitis and vernal keratoconjunctivitis be managed better?	17.86% (25 respondents)	3.91
Q11 How can utilization of corneal donor tissues be improved?	33.57% (47 respondents)	3.98
Q12 How can non-surgical therapy for Corneal endothelial dysfunctions be developed?	32.14% (45 respondents)	4.00
Q13 How can ocular complications associated with Stevens Johnson Syndrome be improved?	10.71% (15 respondents)	4.07
Q14 How can visual outcomes of corneal transplantation be improved?	46.43% (65 respondents)	4.52

Table 1. continued

Q15 How can telemedicine be improved for diagnosis, management and treatment of ocular surface disease ?	16.43% (23 respondents)	5.10
Q16 How can corneal transplant complication related to vaccinations be improved ?	11.43% (16 respondents)	5.33
OPTOMETRIC 194 Respondents		
Q1 Does the enhanced integration of ophthalmic primary and secondary care via community optometric care pathways lead to improved detection, treatment and management of eye disease, and to improved patient quality of life?	77.32% (150 respondents)	1.67
Q2 How can novel medical devices and technology be applied to improve the prevention, diagnosis, and management of eye disease?	66.49% (129 respondents)	1.98
Q3 What are the most appropriate measures of visual function, structure and vision-related quality-of-life for the detection and monitoring of cataracts?	51.55% (100 respondents)	2.34
Q4 How can the detection, diagnosis and management of ocular surface disorders be improved?	41.24% (80 respondents)	2.71
Q5 Can corneal infections be prevented in high-risk individuals such as contact lens wearers?	35.05% (68 respondents)	3.22
Q6 What is the most effective management of ocular complications associated with Stevens Johnson Syndrome?	15.46% (30 respondents)	4.14
REFRACTIVE 107 Respondents		
Q1 What factors influence the development and/or progression of refractive error (short-sightedness, astigmatism, presbyopia and long-sightedness?)	72.90% (78 respondents)	2.20
Q2 How does the wearing of spectacles (of any prescription) affect the progression of refractive error?	61.68% (66 respondents)	3.12
Q3 No intraocular lens provides as good vision and range of vision as the natural human crystalline lens, how can intraocular lens implants be further improved and their outcomes compared in a standardised way?	36.45% (39 respondents)	3.26
Q4 Could the accurate testing of refractive error be made less dependent on a subjective response ie. the person's own response?	48.60% (52 respondents)	3.52
Q5 What are the economic and social burdens of refractive error?	53.27% (57 respondents)	3.45
Q6 Could the accurate testing of refractive error be made less dependent on a subjective response ie. the person's own response?	48.60% (52 respondents)	3.52
Q7 To develop new treatments for presbyopia?	32.71% (35 respondents)	4.13
Q8 What factors influence the development and/ or progression of Keratoconus?	28.04% (30 respondents)	4.13
Q9 What are the long term outcomes of refractive surgery?	33.64% (36 respondents)	4.36
Q10 Are there any alternatives or better treatments for Keratoconus other than corneal collagen cross-linking?	24.30% (26 respondents)	4.40
Q11 There are many types of laser vision correction, does one have better long term outcomes and less risk of complications?	26.17% (28 respondents)	4.41
Q12 Can dry eye after laser vision correction be better treated or prevented?	14.95% (16 respondents)	4.65
Q13 What is the best way to quantify quality of vision objectively before and after refractive surgery?	28.04% (30 respondents)	4.74
Q14 How can biometry (measurement of ocular structures) and selection of the required intraocular lens implant (lens power calculations) be improved?	23.36% (25 respondents)	4.75
Q15 What are the risk factors for corneal ectasia (warping or bulging of the corneal shape) after laser vision correction and when does a cornea become at risk of ectasia following laser vision correction?	12.15% (13 respondents)	6.08

Table 2. Top 10 research priorities for childhood onset*, glaucoma, and neuro-ophthalmology topics.

CHILDHOOD ONSET 177 respondents	% of those responding to this survey who judged this research question to be important	Average ranking of this research question by respondents On a scale of 1–10 (1 most important, 10 least)
Q1 How can the early detection of visual disorders in childhood be improved?	58.19% (103 respondents)	3.43
Q2 What improvements can be made in the assessment of visual function in children, including outcome measures for clinical studies and vision-related quality of life?	47.46% (84 respondents)	3.51
Q3 How can the prevention, diagnosis and treatment of Cerebral Visual Impairment (CVI) in children be improved?	38.98% (69 respondents)	3.52
Q4 How can the prevention, diagnosis and treatment of nystagmus and albinism be improved?	41.24% (73 respondents)	3.64
Q5 How can the prevention, diagnosis and treatment of refractive error in children be improved?	37.85% (67 respondents)	3.82
Q6 How can the prevention, diagnosis and treatment of amblyopia (Lazy eye) be improved?	38.98% (69 respondents)	4.01
Q7 How can genomic medicine be exploited to improve the prevention, diagnosis and treatment of childhood disorders of vision?	41.24% (73 respondents)	4.01
Q8 How can the diagnosis and treatment of inherited retinal disorders be improved?	40.68% (72 respondents)	4.13
Q9 How can the prevention, diagnosis and treatment of ocular, orbital and visual pathway tumours in children be improved?	31.07% (55 respondents)	4.43
Q10 How can the prevention, diagnosis and treatment of visual loss caused by prematurity be improved?	32.77% (58 respondents)	4.45
Q 11 How can 'best practice' be standardised for children with rare visual disorders?	38.42% (68 respondents)	4.57
Q12 How can biomarkers and bioresources be exploited to improve the prevention, diagnosis and treatment of childhood disorders of vision?	28.81% (51 respondents)	4.67
Q13 How can the prevention, diagnosis and treatment of Strabismus be improved?	32.20% (57 respondents)	4.71
Q14 How can the diagnosis and treatment of childhood cataracts be improved?	19.77% (35 respondents)	4.88
Q15 How can the prevention, diagnosis and treatment of optic nerve disorders, including glaucoma, in children be improved?	33.33% (59 respondents)	5.41
GLAUCOMA 651 Respondents		
Q1 What are the most effective treatments for glaucoma and how can treatment be improved?	72.96% (475 respondents)	2.11
Q2 How can any vision loss be restored for people with glaucoma?	65.75% (428 respondents)	2.44
Q3 What can be done to avoid late diagnosis of sight-threatening glaucoma?	54.84% (357 respondents)	2.48

Table 2. continued

Q4 What is the most effective way of monitoring the progression of glaucoma?	64.36% (419 respondents)	2.70
Q5 What causes glaucoma?	53.00% (345 respondents)	2.71
Q6 Is there a link between treatment adherence and glaucoma progression and how can adherence be improved?	32.10% (209 respondents)	3.88
NEURO-OPHTHALMOLOGY		
253 Respondents		
Q1 How can the prevention, diagnosis and treatment of neurodegeneration affecting vision be improved?	54.15% (137 respondents)	2.84
Q2 How can biomarkers and bio-resources be exploited to improve the prevention, diagnosis, monitoring and treatment of adult neuro-ophthalmic disorders?	45.06% (114 respondents)	2.96
Q3 How can the prevention, diagnosis and treatment of acquired optic neuropathies be improved?	43.87% (111 respondents)	2.96
Q4 How can the prevention, diagnosis and treatment of neuroinflammation affecting vision be improved?	42.29% (107 respondents)	3.09
Q 5 How can the prevention, diagnosis and treatment of stroke affecting vision be improved?	46.64% (118 respondents)	3.12
Q 6 How can the prevention, diagnosis and treatment of intracranial tumours affecting vision be improved?	34.39% (87 respondents)	3.16
Q 7 How can the prevention, diagnosis and treatment of hereditary optic neuropathies be improved?	44.66% (113 respondents)	3.36
Q 8 How can the diagnosis and treatment of traumatic brain injury (TBI) affecting vision be improved?	39.53% (100 respondents)	3.72
Q 9 How can the prevention, diagnosis and treatment of strabismus in adults be improved?	29.64% (75 respondents)	3.89

Strengths of this study include the large and diverse stakeholder group involved in each of the topic areas in Phase 1 and the large sample that answered the online survey in Phase 2. Additionally, ranking of the research questions in order of importance offers some insight into their relative importance from the perspective of the respondents. Although significant efforts were made to disseminate the survey to as diverse a group as possible, the representativeness of the sample among the patient population is unknown. For example, socio-economically deprived populations may not be well represented on account of online access and other factors. An additional limitation was the low proportion of non-white respondents. It should also be noted that thyroid eye disease was included among the uveitis section for convenience, yet it is not a uveitic condition.

The next step to be taken by the UK Clinical Eye Research Strategy will be to take the highest priority research questions, and within subspecialties, work up research proposals around these using a Patient/Population/Problem, Intervention/exposure, Comparison/Control, and Outcome measure (PICO) methodology [8, 9]. This is a pressing issue as more commissioned calls for clinical Ophthalmology research will increase the amount of

research funding directed towards Ophthalmology which currently receives significantly less NIHR research grant funding than other medical specialties. This imbalance is a particular concern given the substantial burden of disability caused by eye disease, which in terms of disability-adjusted life-years, is not commensurate with the funding received.

SUMMARY

What was known before

- The Sight Loss and Vision Priority Setting Partnership was formed in 2012 to launch a project for eye research priority setting in collaboration with the James Lind Alliance (JLA).
- In 2013, the Sight Loss and Vision Loss Report published top 10 lists of research priorities across 12 ophthalmology subspecialties following surveys and consultations with more than 2000 ophthalmology stakeholders, supported by the JLA.
- This was the first time in the world that the research priority was set in ophthalmology based on the systematic approach on reaching consensus from the service users and providers.

Table 3. Top 10 research priorities for retina and uveitis topics.

RETINA 595 Respondents	% of those responding to this survey who judged this research question to be important	Average ranking of this research question by respondents On a scale of 1–10 (1 most important, 10 least)
Q1 How can the prevention, diagnosis and treatment of dry age-related macular degeneration be improved?	59.83% (356 respondents)	2.44
Q2 How can the prevention, diagnosis and treatment of wet age related macular degeneration be improved?	55.80% (332 respondents)	2.49
Q3 How can sight loss due to inherited retinal diseases be prevented or restored?	56.64% (337 respondents)	2.54
Q4 Visual rehabilitation in eyes with central visual loss due to retinal diseases?	49.41% (294 respondents)	3.20
Q5 How can the prevention, diagnosis and treatment of diabetic eye disease be improved?	34.45% (205 respondents)	3.25
Q6 Artificial Intelligence in retinal diseases	34.62% (206 respondents)	3.61
Q7 How can the prevention, diagnosis and treatment of macular holes be improved?	36.47% (217 respondents)	3.63
Q8 How can the prevention, diagnosis and treatment of fibrosis as a complication of retinal diseases be improved?	20.67% (123 respondents)	4.06
Q9 How can the prevention, diagnosis and treatment of ocular inflammatory disease be improved?	21.51% (128 respondents)	4.21
Q10 How can the prevention, diagnosis and treatment of ocular melanoma be improved? - Cancer can occur in the eye first or affect the eye from other parts of the body.	15.80% (94 respondents)	5.12
UVEITIS 151 Respondents		
Q1 What are the most effective treatments for ocular and orbital inflammatory diseases?	53.64% (81 respondents)	2.62
Q2 What causes relapse in ocular inflammatory disease and how long should we treat patients?	59.60% (90 respondents)	2.64
Q3 What are the best ways to personalise treatment in uveitis and scleritis?	53.64% (81 respondents)	2.88
Q4 What causes uveitis or scleritis in isolated ocular disease and in systemic disease with associated disease?	55.63% (84 respondents)	2.99
Q5 Which licensed treatments for systemic inflammatory diseases (but not for uveitis) are effective in inflammatory eye disease?	42.38% (64 respondents)	3.12
Q6 What are the most effective biomarkers (imaging / non-imaging) to predict relapse or monitor for disease progression in ocular or orbital inflammatory disease?	48.34% (73 respondents)	3.21
Q7 How can we improve ways to diagnose infectious uveitis?	33.77% (51 respondents)	3.55

Table 3. continued

Q8 What are the most effective scoring systems and clinical outcome measures (imaging / non-imaging) of disease and treatment response in ocular or orbital inflammatory disease?	33.11% (50 respondents)	3.70
Q9 What is the cause and most effective medical management for Thyroid Eye Disease?	18.54% (28 respondents)	4.52

What this study adds

- The NIHR Clinical Research Network's Ophthalmology Specialty Group initiated a UK Clinical Eye Research Strategy in 2020. This strategy started with a major initiative to update the previous James Lind Alliance (JLA) Sight Loss and Vision Priority Setting Partnership.
- 2240 persons responded to a recent online survey that invited respondents to complete one or more of nine subspecialty surveys.
- Respondents indicated which of the research questions they considered important and subsequently ranked them.
- Highest ranked questions by subspecialty: Cataract (prevention), Cornea (improving microbial keratitis treatment), Optometric (impact of integration of ophthalmic primary and secondary care via community optometric care pathways), Refractive (factors influencing development and/or progression of refractive error), Childhood onset (improving early detection of visual disorders), Glaucoma (effective and improved treatments), Neuro-ophthalmology (improvements in prevention, diagnosis and treatment of neurodegeneration affecting vision), Retina (improving prevention, diagnosis and treatment of dry age-related macular degeneration), Uveitis (effective treatments for ocular and orbital inflammatory diseases) A decade after the initial PSP, the results refocus the most important research questions for each subspecialty, and prime targeted research proposals within Ophthalmology.

DATA AVAILABILITY

The data that support the findings of this study are available from the Chair of the UK Clinical Eye Research Strategy, Professor Rupert Bourne; rb@rupertbourne.co.uk upon reasonable request. Data are located in controlled access data storage at Anglia Ruskin University, Cambridge, UK.

REFERENCES

1. Dawson SR, Linton E, Beicher K, Gale R, Patel P, Ghanchi F, et al. Ophthalmology research in the UK's National Health Service: the structure and performance of the NIHR's Ophthalmology research portfolio. *Eye*. 2019;33:610–8.
2. Steinmetz J, Bourne RRA, Briant PS, Flaxman SR, Taylor HRB, Jonas JB, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. *Lancet Glob Health*. 2021;9:e144–e160.
3. Denselow S, Paterson E, Anderson R & Gurmeet K. Funding visual impairment. 2023. <https://www.thinknpc.org/resource-hub/funding-visual-impairment/>.
4. Richard Cable, Mel Pierce. Sight loss and vision priority setting partnership. Setting priorities for eye research Final report. 2023. https://www.jla.nihr.ac.uk/priority-setting-partnerships/sight-loss-and-vision/downloads/SLV-PSP_Final_Report_v111.pdf.
5. Rowe F, Wormald R, Cable R, Acton M, Bonstein K, Bowen M, et al. The sight loss and vision priority setting partnership (SLV-PSP): overview and results of the research prioritisation survey process. *BMJ Open*. 2014;4:e004905.
6. NIHR Ophthalmology. 2023. <https://www.nihr.ac.uk/explore-nihr/specialties/ophthalmology.htm>.
7. UK Clinical Eye Research Strategy. 2023. <https://ukeyresearchstrategy.ac.uk>.
8. Jackson N Unit Five: Asking an Answerable Question. 2023. https://ph.cochrane.org/sites/ph.cochrane.org/files/uploads/Unit_Five.pdf.
9. Azuara-Blanco A, McCorry N, Tatham AJ, Georgoulas S, Founti P, Schweitzer C, et al. European Glaucoma Society research priorities for glaucoma care. *Br J Ophthalmol*. (2023) <https://doi.org/10.1136/bjo-2023-323648>.

ACKNOWLEDGEMENTS

NAVB reports grants made to the University of Liverpool from the NIHR and the Wellcome Trust, and also consulting fees paid to the University of Liverpool from Alimera Sciences and Allergan. RRAB reports research grants from World Health Organization, Royal National Institute of Blind People, Royal National Institute for Deaf People, Thomas Pocklington Trust, Guide Dogs, Deafblind UK, Macular Society, Fight for Sight, Glaucoma UK, Blind Veterans; paid leadership roles as follows: NIHR Clinical Research Network National Specialty Lead for Ophthalmology, NHS England Ophthalmology Improvement Lead East of England; Support for attending meetings received from World Health Organization and the SEVA Foundation; advisory board participation with Santen; payments and honoraria for lectures/education events from Santen, Thea Pharma, AbbVie; Editorial Board member for the journal *Eye*; Faculty member European Glaucoma Society & World Glaucoma Association. SdeS reports Funding via the Thames Valley NIHR Clinical Research Network. SD reports salary funding from Clinical Research Network—NIHR, Oxfordshire South Midlands, grants for salary report as a PI from Eye2Gene NIHR funded, OKKO innovate UK funded, donation from Bayer, consultant to Boehringer Ingelheim, consultant to Allergan, consultant to Circadian Therapeutics, honoraria from Bayer, Novartis, Kyowa safety data monitoring, Leavo Trial, VICI, Lead of Research Education and public Engagement Group for Worshipful Company of Spectacle Makers, Lead of Medical Advisory Board for Retina UK, Bayer to OUHFT June 2023, Novartis to OUHFT nurse/PDT pump. RPG reports a grant from Bayer, Roche and consulting fees from Alimera, Abbvie, Amgen, Apellis, Bayer, Biogen Boehringer Ingelheim, Novartis, Roche. Payment or Honoraria received from Novartis, Apellis, Bayer, Roche, Alimera. FG reports Editorial Board membership of the journal *Eye*. LG reports employment by RNIB a charity that represents people living with sight loss, Employed by SeeAbility a charity that represents people living with sight loss and learning disabilities, Member of the registration committee for GOC. AK reports Glaucoma UK (Co-Investigator) A path to personalised glaucoma care—mapping clinical trial and real-world outcomes to individuals. Glaucoma UK (Chief Investigator) Evaluation of the patient experience of the complication of glaucoma surgery, National Institute for Health Research—Health Technology Assessment (Co-Investigator) Study of technologies for the diagnosis of angle closure glaucoma (ACE) National Institute for Health Research—Health Technology Assessment (Co-Investigator) Glaucoma Risk Prediction in ocular hypertension (GRIP): a cohort study using electronic medical records to validate a risk predictor and determine the cost-effectiveness of different monitoring schemes according to risk of conversion to glaucoma, Lecture fee from Thea Pharma, travel expenses from European Glaucoma Society, personal payments from Thea Pharma and Abbvie for Advisory Board/DMSC, Chairman Glaucoma UK—no payment. AJL reports consulting fees received from Jannsen and payment or honoraria from Roche, support for attending meetings from Roche, is part of a Data Safety and Monitoring committee with Roche and role as Honorary Secretary with Royal College of Ophthalmologists. PJM reports grants received from the Medical Research Council for Biomedical Catalyst: Developmental Pathway Funding Scheme and from the NIHR for eLearning for Clinicians Programme. For patents planned, issued or pending for Visual Field Sensitivity Testing. PJP reports consulting fees from Bayer UK and Roche UK, Payment or honoraria from Bayer UK and Roche UK, Support for attending meetings and/or travel from Bayer UK and Roche UK, Participation on a Data Safety Monitoring Board or Advisory Board with Bayer UK. FJR reports Participation as

Editorial member of Cochrane Library Eyes and Vision Group. PS reports grants from Bayer Ltd 2022-2024. Department has a contract for data analysis of Real-World study of 21 UK centres using Afibercept for Wet AMD and Zeiss Ltd Aug 22. Financial support for an investigator-initiated trial on "Scanning Confocal Ophthalmoscopy for Diabetic Eye Screening (CONCORDIA)". Jan 23. Payment of speaker fees and expenses to attend Bayer conference from Bayer Ltd Oct 22. Payment of speaker fee for the Topcon Global Leadership Programme Topcon Ltd Oct 23. Payment of expenses to attend Euretina from Boehringer Ingelheim Nov 22. Payment of expenses to attend Euretina Boehringer Ingelheim. JS reports Support for attending meetings and/or travel from the NIHR for UK CRN Meetings and also is a Uveitis Study Advisory Board Member and receives Support for Educational meetings and Advisory Boards as Medical Consultant for Roche, Bayer and Alimera. VS reports Co-secretary of UK Paediatric Glaucoma Society Unpaid—voluntary. AJT reports grants from AbbVie and Nova Eye Medical; consulting fees from Thea, AbbVie and Alcon, payment or honoraria from Thea, AbbVie and Viatrix, Participation on a Data Safety Monitoring Board or Advisory Board on Thea, AbbVie and Alcon, Member of European Glaucoma Society Executive Committee, Editorial Board membership of the journal Eye. DV reports Grants for trials Boehringer Ingelheim, Alimera, Roche, Gyroscope paid to Institution (Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust), Speaker fees AbbVie, Roche, Bayer, Travel sponsorships AbbVie, Roche, Bayer, Honorary Treasurer North of England Ophthalmological society and Executive on Clinical Research Network- North East and North Cumbria. AAB reports Member of NICE Interventional Procedures Committee and Member of NIHR HTA CET committee. RRAB reports research grants from World Health Organization, Royal National Institute of Blind People, Royal National Institute for Deaf People, Thomas Pocklington Trust, Guide Dogs, Deafblind UK, Macular Society, Fight for Sight, Glaucoma UK, Blind Veterans; paid leadership roles as follows: NIHR Clinical Research Network National Specialty Lead for Ophthalmology, NHS England Ophthalmology Improvement Lead East of England; Support for attending meetings received from World Health Organization and the SEVA Foundation; advisory board participation with Santen; payments and honoraria for lectures/education events from Santen, Thea Pharma, AbbVie; Editorial Board member for the journal Eye; Faculty member European Glaucoma Society & World Glaucoma Association. MB reports being full time employee of The College of Optometrists, and contributions to the work relating to this paper were done during my working hours. The costs for attending meetings were covered by the College. Lead applicant on grant: NIHR eLearning for Professionals Grant Co-applicant on this grant NIHR funding for DIPP Study. Payment from the Association of Optometrists (AOP) Payment for lecture at the Hospital Optometrists Annual Conference in November 2024. Expenses to cover travel to UK meetings from, NIHR UK CRN Meetings, Trustee of Vision North Somerset (VNS Vision North Somerset is a UK Registered Charity). Role as a Trustee is unpaid. CB reports Editorial Board membership of the journal Eye. RC reports Glaucoma UK Board member as Voluntary role. RPG reports a grant from Bayer, Roche and consulting fees from Alimera, Abbvie, Amgen, Apellis, Bayer, Biogen Boehringer Ingelheim, Novartis, Roche. Payment or Honoraria received from Novartis, Apellis, Bayer, Roche, Alimera. Louise Gow reports Employed by RNIB a charity that represents people living with sight loss, Employed by SeeAbility a charity that represents people living with sight loss and learning disabilities, Member of the registration committee for GOC. AM reports Moorfields Eye Charity awarded UK Clinical Eye Research Strategy Group total of £117,194.02 for this work. Payment made from institution. PJP reports consulting fees from Bayer UK and Roche UK, Payment or honoraria from Bayer UK and Roche UK, Support for attending meetings and/or travel from Bayer UK and Roche UK, Participation on a Data Safety Monitoring Board or Advisory Board with Bayer UK. JS reports Editorial Board membership of the journal Eye. SS reports grants paid to institution from Bayer, Boehringer Ingelheim and consulting fees from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Bayer, Support for attending meetings and/or travel from Roche and Bayer, Participation on a Data Safety Monitoring Board or Advisory Board Bayer, Nova Nordisk, Trustee Macular

Society and Chair RCOphth Scientific Committee, also reports Eyebiotech and Boehringer Ingelheim, and Editorial Board membership of the journal Eye. DV reports Grants for trials Boehringer Ingelheim, Alimera, Roche, Gyroscope paid to Institution (Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust), Speaker fees AbbVie, Roche, Bayer, Travel sponsorships AbbVie, Roche, Bayer, Honorary Treasurer North of England Ophthalmological society and Executive on Clinical Research Network- North East and North Cumbria.

AUTHOR CONTRIBUTIONS

Please see Appendix 3 for more detailed information about individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process.

FUNDING

This study was funded by Fight for Sight, Macular Society and Moorfields Eye Charity.

COMPETING INTERESTS

Production team- please see Declarations at foot of this document listed for each consortium. This paper has not been published elsewhere previously and it is not simultaneously being considered for any other publication.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41433-024-03049-6>.

Correspondence and requests for materials should be addressed to Rupert R. A. Bourne.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

NIHR OPHTHALMOLOGY SPECIALTY GROUP

Ejaz Ansari²², Nick A. V. Beare²³, Rupert R. A. Bourne^{1,2}, Emma Chambers²⁴, Francesca Cordeiro²⁵, Samantha De Silva²⁶, Christiana Dinah^{19,20}, Manjo Doug¹, Susan Downes²⁷, Richard Gale¹⁸, Faruque Ganchi¹⁷, Louise Gow¹⁶, Chris Hammond²⁸, Geraldine V. Hoad¹³, Jonathan Jackson²⁹, Anthony King³⁰, Andrew J. Lotery³¹, Pdraig Mulholland^{10,11}, Ian Nickson³², Praveen Patel¹⁰, Vanessa Poustie²¹, Fiona J. Rowe³³, George M. Saleh⁵, Peter Scanlon³⁴, Brinda Shah³⁵, Julie Vestri³⁶, Velota Sung³⁷, Andrew Tatham³⁸, Marta Ugarte³⁹, Keith Valentine¹⁴, Deepali Varma⁴⁰, Marcela Vortruba⁴¹ and Saila Waseem²⁴

²²Maidstone & Tunbridge Wells NHS Trust, Institute of Medical Sciences, Canterbury Christ Church, University, Maidstone, UK. ²³Eye and Vision Science, University of Liverpool, Liverpool, UK. ²⁴CRN National Coordinating Centre, Leeds, UK. ²⁵Western Eye Hospital, Imperial College London & UCL Institute of Ophthalmology Imperial College Healthcare NHS Trust, London, UK. ²⁶Oxford University Hospitals NHS Foundation Trust, London, UK. ²⁷Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience University of Oxford, Oxford Eye Hospital, John Radcliffe, Oxford, UK. ²⁸Kings College London, London, UK. ²⁹Royal Victoria Hospital, Belfast, UK. ³⁰Nottingham University Hospital, Academic Ophthalmology, University of Nottingham Medical School, Nottingham, UK. ³¹Faculty of Medicine, University of Southampton, Southampton, UK. ³²NIHR Clinical Research Network Coordinating Centre, University of Liverpool, Liverpool, UK. ³³Institute of Population Health, University of Liverpool, Liverpool, UK. ³⁴Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK. ³⁵Somerset NHS Foundation Trust, Yeovil, UK. ³⁶Belfast Health & Social Care Trust, Belfast, UK. ³⁷Birmingham and Midland Eye Centre, Birmingham, UK. ³⁸Princess Alexandra Eye Pavilion and University of Edinburgh, Edinburgh, UK. ³⁹Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK. ⁴⁰Sunderland Eye Infirmary, South Tyneside and Sunderland NHS Foundation Trust, London, UK. ⁴¹University Hospital Wales and Cardiff University, London, UK

EXECUTIVE GROUP OF UK CLINICAL EYE RESEARCH STRATEGY

Augusto Azuara Blanco⁴, Rupert R. A. Bourne^{1,2}, Michael Bowen⁴², Catey Bunce⁴³, Nick Caplin⁴⁴, Roxanne Crosby⁴⁵, Manjo Doug¹, Faruque Ganchi¹⁷, Richard Gale¹⁸, Ali Ghareeb⁴⁶, Renata Gomes⁴⁴, Louise Gow¹⁶, Kerry Hanna⁴⁷, Geraldine V. Hoad¹³, Tina Houlihan⁴⁸, Madina Kara¹⁴, Liying Low⁴⁹, Ailish Murray¹⁵, Praveen Patel¹⁰, Vanessa Poustie²¹, George M. Saleh⁵, James E. Self⁶, Srilakshmi M. Sharma⁸, Sobha Sivaprasad⁷ and Deepali Varma⁴⁰

⁴²The College of Optometrists, London, UK. ⁴³Royal Marsden NHS Foundation Trust, London, UK. ⁴⁴Blind Veterans, London, UK. ⁴⁵Moorfields Eye Hospital, London, UK. ⁴⁶NIHR Trainee Research Network Representative (Northern region), London, UK. ⁴⁷BIOS Research The University of Reading, Reading, UK. ⁴⁸Retina, London, UK. ⁴⁹NIHR Trainee Research Network Representative (Southern region), London, UK.